Zoetis Inc. (BIT:1ZTS)

Market Cap	56.86B
Revenue (ttm)	7.99B
Net Income (ttm)	2.22B
Shares Out	n/a
EPS (ttm)	4.95
PE Ratio	25.56
Forward PE	22.98
Dividend	1.72 (1.37%)
Ex-Dividend Date	Apr 18, 2025

Volume	169
Average Volume	40
Open	128.42
Previous Close	127.16
Day's Range	127.34 - 128.50
52-Week Range	125.66 - 185.04
Beta	n/a
RSI	41.25
Earnings Date	Aug 5, 2025

About Ligand Pharmaceuticals

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph...

• Industry: Pharmaceutical Preparations
• Founded: 1950
• Employees: 13,800
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ZTS

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.